Summary The in vivo administration of somatostatin (SS) or its analogues is capable of suppressing the growth of pancreatic cancer in experimental animals. We examined the effects of SS-14 and its analogue RC-160 on the in vitro growth of two human pancreatic cancer cell lines MiaPaCa-2 and Panc-1 stimulated with epidermal growth factor (EGF) or insulin-like growth factor 1 (IGF-1). Neither SS-14 nor RC-160 inhibited the growth of either cell line. In contrast RC-160 did inhibit the EGF-stimulated growth of a rat pancreatic cancer cell line AR42J. Binding studies with '251-Tyr" somatostatin revealed the presence of a single class of high affinity binding sites with a Kd of 0.20 ± 0.05 nM and a B.,,, of 2.1 + 0.26 pmoles mg-' protein on AR42J but no displaceable binding was observed on MiaPaCa-2 or Panc-1. We conclude that lack of receptors accounts for the failure of SS-14 and RC-160 to influence the growth of human pancreatic cancer in vitro. These results, taken together with other findings, lead us to question the therapeutic efficacy of somatostatin and its analogues as mono-therapy in the treatment of human pancreatic cancer.
Somatostatin (SS) is a tetradecapeptide widely distributed throughout the body, being found in high concentrations in the brain, stomach, intestine and pancreas (Reichlin, 1983) . Somatostatin exerts inhibitory actions on the cellular functions within a variety of tissues including secretion and growth (Konturek et al., 1988; Meyers & Coy, 1980; Schally, 1988) . Somatostatin inhibits the pancreatic exocrine secretion of protein and bicarbonate (Boden et al., 1975) and the endocrine secretion of cholecystokinin, gastrin and secretin (Schally et al., 1978) . These hormones have been shown to have trophic effects on the growth of normal pancreas and also on pancreatic tumours (Johnson, 1981; Schally et al., 1986) . It has therefore been proposed that somatostatin may be capable of inhibiting pancreatic tumour growth indirectly via the suppression of secretion of pancreatic trophic hormones and/or by direct effects on the tumour itself Liebow et al., 1989) . Redding et al. (1984) described the inhibition of both rat and hamster experimental pancreatic cancer growth by the administration of somatostatin-14. Subsequently, Upp et al. (1988) reported that the somatostatin analogue SMS inhibited the growth of two xenografted human pancreatic cancers in nude mice. Singh and colleagues (1991) have since shown that one of these xenografts expressed specific binding sites for somatostatin. It has been claimed that in vitro, somatostatin-14, and its analogue RC-160, reverse the growth-potentiating effects of epidermial growth factor (EGF) on the human pancreatic carcinoma cell line MiaPaCa-2 (Liebow et al., 1986) through the promotion of tyrosine phosphatase activity (Liebow et al., 1989) . For somatostatin to impair directly the growth of pancreatic cancer the cells should therefore express receptors for the peptide. The aim of these study was to determine the somatostatin receptor status of two human (MiaPaCa-2 & Panc-1) and a rat (AR42J) pancreatic cancer cell lines. We have also studied the effects of somatostatin-14 and RC-160 on the proliferation of these three cell lines. and 10 gAl buffer or unlabelled RC-160 (10-6I-0-11 M). Incubation buffer consisted of 50 mM Tris, 0.2% BSA, 0.3 mg ml-' soybean trypsin inhibitor, 0.5 mg ml-' bacitracin and 0.2 mM calcium chloride. The incubation time was 1 h at 30°C. Incubation was terminated by rapid filtration under reduced pressure through Whatman GF/B filters. The filters were washed three times with ice-cold buffer containing 50 mM Tris and 0.2% BSA (pH 7.4). To reduce ligand binding the filter papers were presoaked in 0.5% polyethene-imine overnight. After filtration the filters were dried and counted in a gamma-counter (Packard Cobra).
Materials and methods

Cell
In (Liebow et al., 1986; Redding et al., 1984; Upp et al., 1988; Poston et al., 1990; Szepeshazi et al., 1991 results demonstrate that, contrary to previous reports, MiaPaCa-2 does not express somatostatin receptors and does not respond in vitro to SS-14 and RC-160. We have also shown that this is the case for a second human pancreatic cell line Panc-l.
EGF, TGF-x and IGF-I have been implicated as growth promoting factors for pancreatic cancer. Korc et al. (1986) suggested that enhanced expression of the EGF receptor in human pancreatic cancer may be associated with either structural or numerical alterations in chromosome 7. The same group have also shown that various pancreatic cell lines secrete TGF-a which may therefore act in an autocrine manner as a potent growth promoter (Smith et al., 1987) . The presence of immunoreactive EGF and TGF-c and the overexpression of EGF receptor has also been shown in an archival series of human pancreatic cancers (Barton et al., 1991; Lemoine et al., 1992) . Further confirmatory evidence for this hypothesis was provided by Chen et al. (1990) and Omhura et al. (1990) who also demonstrated a role for IGF-1 as an autocrine factor in pancreatic cancer cell proliferation. It was for these reasons that we used EGF and IGF-I as stimulatory agents for MiaPaCa-2 and Panc-l. A further reason for selecting EGF was the report that somatostatin causes the dephosphorylation of the EGF receptor (Hierowski et al., 1985) thus retarding cell proliferation (Liebow et al., 1986; . Although this has not been demonstrated with IGF-I it might be postulated that somatostatin could effect the IGF-I receptor in a similar fashion because the IGF-1 receptor also has an internal tyrosine kinase domain which is important for stimulating cell growth. We found that neither SS-14 nor RC-160 was capable of inhibiting this growth activation. This is in contrast to the work of Liebow et al. (1986; who have suggested that SS-14 and RC-160 together with another somatostatin analogue, RC-12 1, all inhibit the EGFstimulated growth of MiaPaCa-2. They did not study these effects on the Panc-l cell line. By way of a positive control, we have shown that RC-160 can inhibit the EGF-induced growth of the AR42J rat acinar cell line. This is consistent with the report by Viguerie et al. (1989) who have demonstrated that the somatostatin analogue SMS 201-995 has direct inhibitory effects on AR42J cell proliferation via a mechanism independent of a pertussis toxin sensitive GTPbinding protein.
The present experiments reveal that specific binding sites for somatostatin are absent from the two human ductal pancreatic cancer cell lines. Hierowski et al. (1985) demonstrated somatostatin receptors on MiaPaCa-2 with a very low Bmax value of 3.6 fmole mg-' protein. However these authors did not provide data showing total or non-specific binding curves and no Kd was quoted. Our results are more consistent with the findings of Reubi et al. (1988) who has examined 12 fresh human pancreatic adenocarcinomas none of which contained specific somatostatin receptors.
As part of the internal positive control for these experiments we also performed binding experiments on membranes prepared from the rat acinar tumour cell line AR42J. The data revealed that AR42J possesses somatostatin receptors which consist of a single class of high affinity binding sites with a Kd (0.20 nM) in the range of that observed by other groups (Viguerie et al., 1989) .
Although we chose to study three pancreatic tumour cell lines it is important to emphasise that the effects and response of these cells are not comparable since the AR42J is rat acinar in origin and the MiaPaCa-2 and Panc-1 are human ductal in origin. It should be recalled that 80-90% of cases of pancreatic adenocarcinoma are ductal in origin. Our purpose in studying the AR42J cell line was to exploit this as a positive control in an effort to demonstrate that our assay systems were effective.
It is difficult to explain the inconsistency between previous findings and our findings with the MiaPaCa-2 cell line. One possibility is that the receptor status and characteristics of MiaPaCa-2 cell line have altered with increasing passage number. One previous study has also suggested that there is no growth inhibitory effect of somatostatin on these pancreatic cell lines but this study was conducted on unstimulated cells in serum-free medium at one concentration (Liehr et al., 1990) . However there are no previous reports on the somatostatin receptor expression by the other pancreatic ductal cell line Panc-1 which we also conclude to be devoid of functional binding sites. In conclusion we have found no somatostatin receptors and no growth inhibitory response to somatostatin in two human pancreatic cancer cell lines. This supports the evidence from autoradiographic studies which indicate that very few human pancreatic adenocarcinomas express somatostatin receptors in vivo (Reubi et al., 1988; Singh et al., 1991) . Furthermore a recent clinical trial of RC-160 in patients with pancreatic cancer has at best shown that this agent may cause disease stabilisation of true ductal adenocarcinoma rather than tumour regression . Collectively these finding raise doubts about the role of somatostatin and its analogues as single agent treatment options for the majority of human pancreatic cancers.
